You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
2025 › April › 01
Partners
15 months ago
Leerink Partners analyst David Risinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Trump's tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks ○
Leerink Partners analyst David Risinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks ○
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
page 1 of 1